INTRODUCTION
============

Nicotine has long been known to affect energy balance and weight. Smokers, for example, weigh less than age- and sex-matched non-smokers ([@B1]), while smoking cessation is associated with increased food intake and weight gain ([@B72]; [@B85]; [@B20]). Given the strong link between smoking and reduced weight, many report using smoking for weight control, or avoid cessation due to fear of weight gain ([@B8]; [@B86]; [@B25]). Experimentally, nicotine has been shown to suppress appetite, increase energy expenditure, and alter feeding patterns, which can lead to weight loss ([@B37]; [@B91]). Despite these known effects, however, the mechanisms underlying nicotine's effects on eating behaviors and obesity remain unclear. Nicotine acts on both high-affinity nicotinic cholinergic receptors, such as the α4-β2 receptor, and low-affinity receptors, such as the α7 receptor, both centrally and peripherally. Recent studies suggest that the alpha-7 nicotinic acetylcholine receptor (α7nAChR) may play a particularly prominent role in nicotinic effects on eating behaviors. As such, this review focuses on neuronal effects of nicotinic agents, especially those involving the α7nAChR, how stimulation of this receptor influences eating behaviors and weight, and the potential utility of α7nAChR agonists as a novel treatment strategy for obesity.

ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTORS
=========================================

Neuronal nicotinic acetylcholine receptors consist of ligand-gated ion channels that are activated by acetylcholine, but also respond to nicotine and similar compounds. These receptors are comprised of five transmembrane subunits arranged around a central pore ([@B59]; [@B14]). These subunits include αβ combinations (α2--α6 and β2--β4), homomeric nAChRs (α7--α9), and a heteromer α combination (α9 with α10) ([@B50]; [@B36]; [@B14]). The two main types of nAChRs found in the brain are α4--β2 receptors and α7 receptors ([@B34]; [@B10]). While different nAChR subtypes may affect circuits involved in feeding behavior ([@B37]; [@B52],[@B53]; [@B91]), this review will focus on α7nAChRs, which are receiving increased research attention for their involvement in eating behaviors and food intake.

CENTRAL EFFECTS OF α7nAChRs ON EATING BEHAVIORS
===============================================

Previous reviews have described peripheral effects of nicotine and other α7nAChR agonists on obesity and eating behaviors ([@B2]; [@B43]). As such, while recent evidence for peripheral effects will be briefly examined, the primary focus of this review will be on central effects. Overall, nicotine and other α7nAChR agonists appear to suppress appetite through numerous complex, interacting central pathways, particularly those in the hypothalamus, which plays a fundamental role in energy balance. When various interactions are jointly considered, activation of hypothalamic α7nAChRs is thought to result in overall increased inhibition of appetite circuits, resulting in decreased food intake ([@B37]). Stimulation of α7nAChRs may also reduce food intake via effects on reward pathways or cortical networks involved in eating behaviors.

α7nAChR EFFECTS ON HYPOTHALAMIC NEUROPEPTIDES
=============================================

Hypothalamic nuclei most associated with energy balance and feeding regulation include the lateral hypothalamus (LH), ventromedial hypothalamus (VMH), arcuate nucleus (ARC), and paraventricular nucleus (PVN). The LH is often simplistically described as the "hunger center" and the VMH the "satiety center" ([@B68]; [@B91]). The ARC is a primary center for peripheral feeding signal integration (e.g., leptin, insulin) and contains neurons that stimulate feeding and those that inhibit feeding when activated, with projections to the PVN and LH ([@B68]; [@B39]; [@B91]).

A primary potential pathway for α7nAChR mediation of eating behaviors involves hypothalamic cholinergic input. The hypothalamus contains rich cholinergic innervation and some of the highest levels of α7nAChR expression in the brain ([@B64]). Appetite-related circuits within the hypothalamus can be modulated by nAChR activation, with a complex network of hormone and neuropeptide signals exerting neuronal effects to regulate eating behaviors. A number of studies have demonstrated effects of nicotine on these signals. Here, we will discuss α7nAChR involvement in cholinergic effects on proopiomelanocortin (POMC), neuropeptide Y (NPY), and melanin-concentrating hormone (MCH), all of which are involved in feeding regulation (**Figure [1](#F1){ref-type="fig"}**).

![**Effects of α7nAChR stimulation on hypothalamic neuropeptide and neurotransmitter release.** Although there are complex interactions among pathways, it is hypothesized that the net effect of α7nAChR stimulation leads to reduced food intake. Inhibitory effects are indicated with a minus sign, while excitatory effects are indicated with a plus sign. Note that both inhibitory and excitatory effects of α7nAChR stimulation have been observed on NPY. While appetite effects of dopamine elsewhere in the brain are mixed, studies suggest that hypothalamic dopamine release contributes to appetite inhibition. α7nAChR, α7 nicotinic acetylcholine receptor; GABA, gamma aminobutyric acid; NPY, neuropeptide Y; POMC, proopiomelanocortin; 5-HT, serotonin; Glu, glutamate; MCH, melanin-concentrating hormone; DA, dopamine.](fpsyg-05-00553-g001){#F1}

POMC AND NPY
------------

Nicotine may suppress appetite via activation of POMC neurons. POMC is produced in the hypothalamus ([@B32]; [@B91]) and is a precursor for melanocortins, such as α-melanocyte-stimulating hormone (α-MSH), associated with suppressed food intake ([@B68]; [@B91]). Electrophysiologically, [@B32] demonstrated that nicotine excites mouse hypothalamic POMC neurons and that α7nAChRs are present on these neurons. Nicotine effects were reduced by the α7nAChR antagonist methyllycaconitine (MLA), suggesting at least partial mediation by α7nAChRs. As such, POMC stimulation is a potential mechanism through which α7nAChR agonism may suppress appetite. It should be noted, however, that MLA is not as selective an antagonist for α7nAChRs as α-bungarotoxin ([@B41]; [@B54]), which should be considered when MLA is used to assess α7nAChR effects.

Neuropeptide Y, also produced in the hypothalamus, is associated with increased food intake ([@B68]). NPY neurons in the ARC project to the PVN to stimulate feeding ([@B55]; [@B39]). Thus, POMC and NPY have opposing effects on food intake. Smokers show reduced NPY levels compared to non-smokers, and smoking cessation is associated with increased NPY ([@B33]), suggesting NPY inhibition as a mechanism for appetite suppression. However, nicotine effects on NPY are complex. As with POMC, NPY neurons in the hypothalamus are stimulated by nicotine and express α7nAChRs. Excitation of NPY neurons by nicotine is partially mediated by α7nAChRs, as MLA reduces excitation. Although nicotine reduces hypothalamic NPY mRNA in rats acutely ([@B23]), NPY mRNA *increases* with chronic administration ([@B23]; [@B44]), which is accompanied by *decreased* food intake ([@B44]). This is counterintuitive, as NPY stimulates food intake. However, nicotine also reduces hypothalamic NPY receptor density ([@B40]), which could explain the decreased intake. Another explanation for the net appetite-inhibiting effect of nicotine is that the depolarizing effect of nicotine on POMC neurons (anorexigenic) is significantly greater than that on NPY neurons (orexigenic). Furthermore, in addition to NPY neuron excitation by nicotine, inhibition of excitatory synaptic activity (glutamate release) on NPY neurons was also observed, an effect not seen in POMC neurons ([@B32]). Thus, although nicotine can excite NPY neurons, the greater direct excitation of appetite-inhibiting POMC neurons compared to appetite-stimulating NPY neurons, in addition to indirect inhibition of NPY neurons (via reduced glutamate release) may contribute to the net effect of appetite inhibition by nicotine and other α7nAChR agonists.

MELANIN-CONCENTRATING HORMONE
-----------------------------

Melanin-concentrating hormone (MCH) neurons are primarily located in the LH ([@B90]) and also stimulate food intake ([@B62]). MCH may have a particular role in reward-related aspects of food, as MCH neurons project to the nucleus accumbens (NAC) and the ventral tegmental area (VTA), brain areas involved in reward processes ([@B67]; [@B38]). MCH knockout mice are excessively lean and demonstrate reduced food intake ([@B70]; [@B48]). α7nAChRs may mediate gamma aminobutyric acid (GABA)-related inhibition of MCH neurons in the LH, leading to this appetite suppression ([@B38]).

α7nAChR MODULATION OF NEUROTRANSMITTERS INVOLVED IN FOOD INTAKE BEHAVIORS
=========================================================================

In addition to hypothalamic neuropeptides, nicotine modulates effects of multiple other neurotransmitter systems in the brain. The following section describes the impact of nicotine on GABA, glutamate, dopamine (DA), and serotonin, focusing on how α7nAChRs may inhibit appetite by modulating these neurotransmitter systems.

GAMMA AMINOBUTYRIC ACID
-----------------------

Release of GABA, the main inhibitory neurotransmitter in the brain, is influenced by nAChRs ([@B50]; [@B36]). Nicotine effects on appetite reduction may be associated with decreased excitability of MCH neurons in the LH via increased GABAergic inhibitory tone. [@B38] found nicotine administration to facilitate GABAergic transmission in adult mice, and prenatal nicotine exposure to enhance postnatal GABAergic transmission. Specific involvement of α7nAChRs was also demonstrated, as an α7nAChR-specific antagonist (α-bungarotoxin) blocked these effects. As such, activation of α7nAChRs on GABAergic terminals in the hypothalamus may contribute to the anorexigenic effects of nicotine.

GLUTAMATE AND DOPAMINE
----------------------

Glutamate is the main excitatory neurotransmitter in the brain and plays a role in rewarding effects of nicotine, as nicotine increases glutamate release in the VTA and NAC, brain regions central to reward mechanisms ([@B50]; [@B63]; [@B65]). High concentrations of α7nAChRs are observed in the VTA ([@B12]; [@B16]; [@B67]; [@B35]) and are thought to mediate nicotine-associated glutamate release ([@B50]; [@B65]). α7nAChR-mediated glutamate release plays a large role in nicotine's effects on DA, a neurotransmitter critical in the reinforcing effects of nicotine ([@B67]; [@B22]). α4-β2nAChRs are sufficient for these reinforcing effects ([@B3]), likely via direct effects on DA neurons ([@B87]; [@B3]). However, stimulation of α7nAChRs activates DA neurons via glutamatergic inputs ([@B89]; [@B65], [@B66]; [@B29]). Thus, α7nAChR activation ultimately increases DA, but this is largely mediated via glutamatergic effects. Additionally, α7nAChRs may be important in dopaminergic function following long-term nicotine exposure, as they are more resistant to desensitization at usual levels for smokers than nAChR subunits containing β2 receptors, and may prevent dopaminergic hypoactivation resulting from chronic β2 desensitization ([@B4], [@B3]).

The role of α7nAChR-mediated glutamate release in food consumption remains unclear. Administration of a glutamate *antagonist* has been found to increase food intake in rats ([@B46]; [@B73]). As such, glutamate release stimulated by an α7nAChR *agonist* could decrease food intake. Increased DA release, amplified by α7nAChR-mediated glutamate release, increases the reward value of food ([@B89]; [@B67]). [@B61] observed striatal DA release in mice following administration of an α7nAChR agonist (choline), an effect not observed in mice lacking α7nAChRs. Food-induced DA release is attenuated by an α7nAChR antagonist (MLA), implicating α7nAChRs in eating-related reward ([@B67]). However, the role of DA in feeding behaviors is complex and varies by brain region. Although DA contributes to rewarding aspects of food intake in areas such as the VTA and NAC, hypothalamic DA release is though to contribute to nicotine-related reductions in food intake ([@B51]; [@B68]). Thus, further study is needed to determine if effects of α7nAChRs on DA lead to overall increased or decreased consumption.

SEROTONIN
---------

Serotonin inhibits food intake ([@B80]; [@B37]), likely by promoting satiety (i.e., meal stopping; [@B71]). One mechanism may be via NPY, as evidence suggests serotonin inhibits NPY release ([@B19], [@B17],[@B18]). Nicotine-induced nAChR activation can increase serotonin release, contributing to appetite suppression ([@B74]; [@B37]). Activation of α7nAChRs is thought to influence serotonin release, as α7nAChRs have been identified on serotonergic neurons ([@B26]) and α7nAChR stimulation increases serotonin release in the dorsal raphe nucleus ([@B45]).

CORTICAL α7nAChR INVOLVEMENT IN FOOD INTAKE BEHAVIORS
=====================================================

Cortically, α7nAChR activation may affect limbic and paralimbic brain systems such as the insula and cingulate cortex, which also play a role in reward aspects of eating behaviors ([@B79]) and contain rich cholinergic innervation ([@B58]).

INSULA/SALIENCE NETWORK
-----------------------

The insula, containing primary taste cortex, is involved in eating behavior regulation, including involvement in rewarding aspects of food and food-related arousal ([@B76]; [@B31]; [@B13]). The insula is also a central component of the salience network, an intrinsic brain network involved in assessing relevance of internal and external stimuli ([@B69]; [@B6]), in which altered response has been observed in obese, compared to lean, individuals ([@B27]; [@B42]). The insula is associated with urges and cravings related to both food and drugs of abuse ([@B60]; [@B56]; [@B21]). Indeed, smokers sustaining insula damage following a stroke showed little subsequent difficulty quitting smoking, suggesting a role for the insula in effects of nicotine ([@B57]). However, the role of α7nAChRs in the insula is not yet known. Via α-bungarotoxin binding, studies have found α7nAChRs in the insula in both rats ([@B24]) and monkeys ([@B30]). Presence of α7nAChRs in the human insula has been suggested by detection of α7nAChR mRNA ([@B83]), but insular α7nAChR protein levels have not yet been studied in humans. As such, further study of α7nAChRs in the insula, and how activation of these receptors relates to eating behaviors, is needed.

POSTERIOR CINGULATE/DEFAULT MODE NETWORK
----------------------------------------

The posterior cingulate cortex may also be involved in eating behaviors, having been associated with neuronal responses to visual food cues and taste ([@B76]; [@B15]; [@B13]). The posterior cingulate is also a key component of the default mode network (DMN), an intrinsic brain network involved in self-referential thoughts and attention to internal stimuli ([@B7]). DMN activity may play a role in eating behaviors, as overactivity of this network has been observed in obese, compared to lean, individuals ([@B77]). Furthermore, this activity, which was associated with measures of appetite, was shown to change in response to feeding in lean, but not obese individuals. Nicotine can reduce resting-state DMN activity, including the posterior cingulate ([@B75]). α7nAChRs are present in high concentrations in the cingulate cortex, as assessed by α-bungarotoxin binding ([@B5]; [@B49]). A study of DMN activity in schizophrenia patients observed reduced response following treatment with an α7nAChR partial agonist \[3-2,4-dimethoxybenzylidene anabaseine (DMXB-A)\], specifically in the posterior cingulate ([@B78]). As with non-mentally ill obese individuals, DMN overactivity has been observed in schizophrenia patients ([@B28]; [@B84]), who are obese are rates twice those observed in the general population. Given these findings, it is possible that activation of α7nAChRs could be a mechanism to normalize DMN hyperactivity in obesity.

α7nAChRs AND PERIPHERAL FACTORS INVOLVED IN EATING BEHAVIORS AND OBESITY
========================================================================

Recent studies have discovered a key role for α7nAChRs in peripheral factors related to obesity. In a mouse model of diabetes, [@B47] found that an α7nAChR-selective agonist (TC-7020) reduced weight gain and food intake, as well as glucose and triglyceride levels and expression of proinflammatory cytokines. These effects were reversed by an α7nAChR antagonist (MLA), supporting α7nAChR involvement. In humans, [@B9] have also found evidence supporting α7nAChR involvement in obesity. In addition to identifying α7nAChR expression in human mature adipocytes, they found that expression was downregulated in obese compared to lean adults, and that weight loss partially restored α7nAChR expression.

A potential mechanism through which peripheral α7nAChRs may exert weight and food intake effects is by mediating anti-inflammatory effects. Inflammation is a key feature of obesity, associated with increased proinflammatory cytokine production, insulin resistance, and development of type 2 diabetes ([@B47]; [@B82]). Activation of α7nAChRs on cytokine-producing cells, such as macrophages, mediates this inflammatory response by inhibiting inflammatory cytokine production ([@B82]). A number of studies have demonstrated anti-inflammatory effects of nicotine ([@B81]; [@B43]) and smokers may have a reduced risk of some inflammatory diseases such as ulcerative colitis ([@B43]). The "cholinergic anti-inflammatory pathway" can be activated by α7nAChR agonists ([@B11]). Supporting this, nicotine-induced cytokine inhibition can be blocked by α7nAChR-specific antagonists ([@B11]), and α7nAChR knockout mice show increased LPS-induced proinflammatory cytokine production, including TNFα and IL-1β ([@B81]). [@B82] found adipose tissue and macrophages in mice to express α7nAChRs, and while nicotine suppressed proinflammatory cytokine production, this effect was not observed in α7nAChR knockout mice. Additionally, nicotine reduced adipose tissue inflammation and improved insulin sensitivity in obese mice. [@B88] observed improved insulin sensitivity in rodents following treatment with either nicotine or an α7nAChR agonist (PNU-282987), an effect not observed in α7nAChR knockout animals. These studies suggest that α7nAChRs are critical in anti-inflammatory effects of nicotine. Given this, therapeutics targeting α7nAChRs are increasingly being explored for diseases involving inflammation, such as diabetes, arthritis, and ulcerative colitis ([@B81]; [@B47]; [@B2]; [@B43]).

CONCLUSION
==========

The α7nAChR plays an important role in both central and peripheral mechanisms involved in eating behaviors and energy balance. Studies have found links between α7nAChR expression and obesity, insulin resistance, and diabetes. Centrally, α7nAChRs modulate hypothalamic neuropeptides and neurotransmitters involved in feeding regulation and play a role in cortical processes affecting intake behavior. Overall, although the circuits involved are complex, it appears that net effects of nicotine and other α7nAChR agonists result in appetite suppression, which could lead to weight loss. Peripherally, and perhaps also centrally, α7nAChRs are also an important mediator of inflammation, a key contributor to health problems in obesity.

Although α7nAChR agonists have not yet been investigated for eating behavior effects in humans, preliminary animal work supports this idea, finding peripheral effects such as improved insulin sensitivity ([@B82]; [@B88]) and reduced weight gain and metabolic changes in a model of diabetes ([@B47]). Further support for extending α7nAChR studies to humans lies in the observation that α7nAChRs are downregulated in human obesity, but normalize with weight loss ([@B9]). In conclusion, given nicotine's effects in humans, experimental support for α7nAChR involvement in eating behavior regulation, and early evidence of α7nAChR agonist effects in animal studies, the α7nAChR may represent a promising new therapeutic target for weight management and the treatment of obesity in humans.
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